The local medical community is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing significant results in clinical trials for treating obesity. This medication suggests a https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/